Ajax Therapeutics and Schrödinger, announced an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target. The partnership was established...
Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel, selective small molecules for myeloproliferative neoplasms (MPNs), announced the...
